SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network (AVT) is experiencing heightened community interest, largely fueled by recent announcements including the incorporation of its DAO in the UAE and the strategic appointment of Dr. Marwan Al Zarouni to deepen its presence in the region. The community is actively discussing the potential for a significant breakout, emphasizing AVT's low market capitalization, robust Polkadot integration, and the expanding utility driven by its enterprise-focused Aventus Cloud offerings.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to the highly anticipated and successful orbital launch of its BlueBird 6 satellite, a pivotal step in the direct-to-device cellular broadband race. This milestone, which significantly enhances network capabilities, has fueled strong bullish sentiment among investors eager for future expansion, though some remain watchful of the long-term path to profitability amid current valuations.

TOSHI

TOSHI, known as the 'Face of Base,' is trending with its community actively 'buying the dip' amidst recent market volatility, sparking discussions around its resilience. Despite current price action, strong long-term conviction persists, fueled by anticipation of future catalysts like major exchange listings and the upcoming Toshi Mobile launch.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending following its recent exclusive licensing agreement for Vaxart's novel oral COVID-19 vaccine program and the authorization of a new $100 million share repurchase program. Investors are actively discussing the potential of this oral vaccine platform to transform the market, especially with promising early Phase 1/2 data for its shingles candidate, Z-1018, showing strong immune responses and better tolerability compared to an existing vaccine. While many see these as significant growth catalysts, community discussions also highlight a history of management performance concerns and the ongoing proxy fight initiated by Deep Track Capital.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending due to the Pipeline Hazardous Materials Safety Administration (PHMSA) granting approval for the Las Flores Pipeline restart, effectively shifting regulatory authority from California to federal oversight. This is seen by the community as a "game-changing" catalyst, de-risking the company's offshore oil assets and igniting speculation of a significant short squeeze and revaluation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing heightened trading activity and intense community discussion, largely fueled by the release of Epstein-related documents and the resulting allegations against Donald Trump. While many investors are expressing strong bearish sentiment citing these claims, others are dismissing the controversy as political noise and highlighting the company's recent merger for its future potential.

Avient Corp. engages in the business of thermoplastic compounds. It operates through the Color, Additives, and Inks and Specialty Engineered Materials segments. The Color, Additives, and Inks segment provides custom color and additive concentrates in solid and liquid form for thermoplastics, dispersions for thermosets, specialty inks, plasticols, and vinyl slush molding solutions. The Specialty Engineered Materials segment makes polymer formulations, services, and solutions for designers, assemblers, and processors of thermoplastic materials. The company was founded on August 31, 2000 and is headquartered in Avon Lake, OH.

Avient Corp

Avient (AVNT) is trending as the market reacts positively to recent strong financial performance and multiple analyst upgrades, underscoring the company's strategic shift toward organic growth in specialty materials. The community is actively discussing bullish technical signals, including significant volume and a 'coiled spring' pattern, with many anticipating further upside. This renewed interest is fueled by Avient's focus on innovative and sustainable solutions, positioning it favorably in evolving markets.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is drawing attention due to contrasting news, as its MS drug tolebrutinib faced regulatory delays and a Phase III trial setback, while its blockbuster Dupixent continues to secure new approvals and expanded indications globally. Amid these pipeline developments, the community is actively discussing Sanofi's strategic acquisitions, notably a major deal in immunology, alongside ongoing speculation about potential future targets in the dynamic biotech sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending on news of its upcoming inclusion in the S&P MidCap 400 index, driving significant community discussion around potential institutional buying and enhanced visibility. This development, coupled with its recent strong earnings report, first GAAP profit, and leadership in Agentic AI, fuels widespread bullish sentiment, with many anticipating substantial long-term growth and a potential short squeeze.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending after recently pausing its aggressive Bitcoin accumulation, instead raising significant cash reserves through share sales. This strategic shift has ignited intense community debate, with many questioning shareholder dilution and the stock's pronounced underperformance relative to Bitcoin, despite trading at a discount to its vast crypto holdings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now

Merit Medical shows resilience despite 2025 share pressure, supported by cardiovascular growth, margin expansion and WRAPSODY CIE momentum.

Zacks.com featured highlights include NVIDIA, Ralph Lauren, Expedia and Cencora

NVIDIA leads a group of stocks near 52-week highs, as Zacks highlights momentum-driven upside potential alongside Ralph Lauren, Expedia and Cencora.

Patton Fund Management Inc. Trims Position in Cencora, Inc. $COR

Patton Fund Management Inc. lowered its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 91.8% during the third quarter, according to the company in its most recent Form 13F filing...

Cencora, Inc. $COR Shares Sold by Coho Partners Ltd.

Coho Partners Ltd. lessened its stake in Cencora, Inc. (NYSE:COR - Free Report) by 43.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The...

Cencora (NYSE:COR) EVP Sells 3,351 Shares

Cencora, Inc. (NYSE:COR - Get Free Report) EVP Elizabeth Campbell sold 3,351 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a...

Silvana Battaglia Sells 1,677 Shares of Cencora (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR - Get Free Report) EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for...

Cencora (NYSE:COR) CEO Robert Mauch Sells 5,096 Shares

Cencora, Inc. (NYSE:COR - Get Free Report) CEO Robert Mauch sold 5,096 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $343.45, for a total...

Cencora (NYSE:COR) EVP Elizabeth Campbell Sells 3,351 Shares

Cencora, Inc. (NYSE:COR - Get Free Report) EVP Elizabeth Campbell sold 3,351 shares of the business's stock in a transaction on Friday, December 19th. The stock was sold at an average price of...

4 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like NVDA, RL, EXPE and COR are seeing price strength and have a high chance of carrying the momentum forward.

Wedge Capital Management L L P NC Sells 21,403 Shares of Cencora, Inc. $COR

Wedge Capital Management L L P NC lowered its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 19.5% during the 3rd quarter, according to the company in its most recent filing with the...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Current Price	$340.59
Prev Close	$340.03
Open	$337.52
Dividend Yield	0.70%
50-Day Moving Average	$346.42
Beta	0.05
Avg. Volume	1.66M
PE Ratio	42.83

52-Week High	$377.54
52-Week Low	$223.92
Market Capitalization	$94.06B
EPS (Annual)	$7.96
Price to Book	43.80
Revenue Per Employee	$6.3M
Enterprise Value/EBITDA	N/A

COR
Cencora Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest COR News

CORCencora Inc.